Ista gains FDA approval of once-daily bromfenac eye drops, to replace Xibrom
This article was originally published in Scrip
Executive Summary
The ophthalmic specialty company Ista Pharmaceuticals has gained FDA approval of its supplemental new drug application for Bromday (bromfenac ophthalmic solution 0.09%), a once-daily formulation of the NSAI that it already markets in a twice-daily formulation under the brand name Xibrom.